Literature DB >> 9751496

Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells.

M H Jeng1, M A Shupnik, T P Bender, E H Westin, D Bandyopadhyay, R Kumar, S Masamura, R J Santen.   

Abstract

Hormone-dependent breast cancer responds to primary therapies that block estrogen production or action, but tumor regrowth often occurs 12-18 months later. Additional hormonal treatments that further reduce estrogen synthesis or more effectively block its action cause additional remissions, but the mechanisms responsible for these secondary responses are not well understood. As a working hypothesis, we postulated that primary hormonal therapy induces adaptive changes, resulting in enhanced estrogen receptor (ER) expression and target gene activation and, further, that secondary treatment modalities interfere with these receptor-mediated transcriptional pathways. To test this hypothesis, we used an MCF-7 breast cancer model system involving deprivation of estradiol in culture for a prolonged period. These long-term estradiol-deprived (LTED) cells adapt by acquiring the ability to regrow in the absence of added estradiol. The experimental paradigm involved the comparison of wild-type cells with LTED cells. As endpoints, we directly assessed ER expression at the messenger RNA-, protein-, and ligand-binding levels and ER functionality by quantitating reporter gene activation and expression of endogenous estrogen target gene messenger RNA, as well as ER coactivator levels. Our data demonstrated an adaptive increase in ER expression and in basal ER functionality, as assessed by read-out of three different transfected reporters in LTED, as opposed to wild-type MCF-7 cells. Increased reporter gene read-out was dramatically inhibited by the pure antiestrogen ICI 182,780. As verification that endogenous (as well as transfected) estrogen target genes had enhanced transcription, we found that the basal levels of c-myb and c-myc message were substantially increased in LTED cells and could be inhibited by antiestrogen. Interestingly, the levels of c-myb and c-myc message in the LTED cells seemed to be increased out of proportion to the degree of ER reporter gene activation and were similar to those in wild-type cells maximally stimulated with estradiol. In addition, not all estrogen-responsive genes were activated, because transforming growth factor-alpha message level was not increased in LTED cells. Up-regulation of the steroid receptor coactivator SRC-1 did not seem to mediate the process of enhanced ER-induced transcription. Considering these observations together, we suggest that long-term estradiol deprivation causes adaptive processes that not only involve up-regulation of the ER but also influence the specificity and magnitude of activation of estrogen-responsive genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751496     DOI: 10.1210/endo.139.10.6229

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  49 in total

1.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Authors:  Todd W Miller; Bryan T Hennessy; Ana M González-Angulo; Emily M Fox; Gordon B Mills; Heidi Chen; Catherine Higham; Carlos García-Echeverría; Yu Shyr; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Estrogen receptor alpha gene polymorphisms are associated with type 2 diabetes and fasting glucose in male subjects.

Authors:  Reza Meshkani; Hamzeh Saberi; Narges MohammadTaghvaei; Mohammad Amin Tabatabaiefar
Journal:  Mol Cell Biochem       Date:  2011-08-12       Impact factor: 3.396

Review 3.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

Review 4.  Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.

Authors:  Richard J Santen; Robert X Song; Shigeru Masamura; Wei Yue; Ping Fan; Tetsuya Sogon; Shin-ichi Hayashi; Kei Nakachi; Hidtek Eguchi
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

5.  Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Authors:  Suzanne E Wardell; Matthew J Ellis; Holly M Alley; Koleen Eisele; Todd VanArsdale; Stephen G Dann; Kim T Arndt; Tina Primeau; Elizabeth Griffin; Jieya Shao; Robert Crowder; Jin-Ping Lai; John D Norris; Donald P McDonnell; Shunqiang Li
Journal:  Clin Cancer Res       Date:  2015-05-19       Impact factor: 12.531

6.  Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.

Authors:  Ping Fan; Wei Yue; Ji-Ping Wang; Sarah Aiyar; Yan Li; Tae-Hyun Kim; Richard J Santen
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

7.  Demethylation of promoter C region of estrogen receptor alpha gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells.

Authors:  Tetsuya Sogon; Shigeru Masamura; Shin-Ichi Hayashi; Richard J Santen; Kei Nakachi; Hidetaka Eguchi
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-16       Impact factor: 4.292

Review 8.  Estrogen receptor alpha in human breast cancer: occurrence and significance.

Authors:  S Ali; R C Coombes
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

Review 9.  Fulvestrant and the sequential endocrine cascade for advanced breast cancer.

Authors:  S Johnston
Journal:  Br J Cancer       Date:  2004-03       Impact factor: 7.640

Review 10.  Key signalling nodes in mammary gland development and cancer: Myc.

Authors:  Nancy E Hynes; Tina Stoelzle
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.